148 related articles for article (PubMed ID: 19778431)
1. Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients.
Lin Y; Yin W; Yan T; Zhou L; Di G; Wu J; Shen Z; Shao Z; Lu J
BMC Cancer; 2009 Sep; 9():342. PubMed ID: 19778431
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients.
Yin WJ; Lu JS; Di GH; Lin YP; Zhou LH; Liu GY; Wu J; Shen KW; Han QX; Shen ZZ; Shao ZM
Breast Cancer Res Treat; 2009 May; 115(2):325-33. PubMed ID: 18563552
[TBL] [Abstract][Full Text] [Related]
3. Pattern of metastatic spread in triple-negative breast cancer.
Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
[TBL] [Abstract][Full Text] [Related]
4. Is conservative surgery a good option for patients with "triple negative" breast cancer?
Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
[TBL] [Abstract][Full Text] [Related]
5. Locoregional Recurrence Patterns in Patients With Different Molecular Subtypes of Breast Cancer.
Cheun JH; Kim HK; Moon HG; Han W; Lee HB
JAMA Surg; 2023 Aug; 158(8):841-852. PubMed ID: 37342035
[TBL] [Abstract][Full Text] [Related]
6. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
Press DJ; Miller ME; Liederbach E; Yao K; Huo D
Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
[TBL] [Abstract][Full Text] [Related]
7. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
8. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
9. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
10. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
Haffty BG; Yang Q; Reiss M; Kearney T; Higgins SA; Weidhaas J; Harris L; Hait W; Toppmeyer D
J Clin Oncol; 2006 Dec; 24(36):5652-7. PubMed ID: 17116942
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
Li X; Zhang X; Liu J; Shen Y
BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
[TBL] [Abstract][Full Text] [Related]
12. Role of locoregional surgery in patients with de novo stage IV breast cancer: analysis of real-world data from China.
Ma L; Mi Y; Cui S; Wang H; Fu P; Yin Y; Jin F; Li J; Liu Y; Fan Z; Zhang H; Geng C; Jiang Z
Sci Rep; 2020 Oct; 10(1):18132. PubMed ID: 33093581
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
14. Time-varying pattern of recurrence risk for Chinese breast cancer patients.
Yin W; Di G; Zhou L; Lu J; Liu G; Wu J; Shen K; Han Q; Shen Z; Shao Z
Breast Cancer Res Treat; 2009 Apr; 114(3):527-35. PubMed ID: 18425576
[TBL] [Abstract][Full Text] [Related]
15. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
[TBL] [Abstract][Full Text] [Related]
16. Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China.
Tang LC; Jin X; Yang HY; He M; Chang H; Shao ZM; Di GH
BMC Cancer; 2015 Mar; 15():201. PubMed ID: 25885213
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
19. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]